Free Health Updates
Skip to main content
Table of Contents
< All Topics
Print

Do Research Reviews Recommend Cannabis for Dementia? 

Posted
Updated
ByMy Patient Advice
Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

Interest in cannabis-based medical products as a potential treatment for dementia has grown in recent years, but expert reviews continue to emphasise one key message: the evidence is not strong enough to recommend cannabis for dementia care. According to NHS and NICE guidance, cannabinoids such as THC, CBD, and nabilone are not recommended for cognitive symptoms, agitation, or behavioural disturbances in people with dementia (NICE NG97; NICE NG144). 

Can medical cannabis be accessed legally for women’s health?

What The Reviews Are Assessing 

Research reviews and meta-analyses generally explore whether cannabinoids can improve symptoms such as agitation, anxiety, or sleep disturbance, collectively known as behavioural and psychological symptoms of dementia (BPSD). These symptoms are common in advanced dementia and often distressing for both patients and caregivers. 

However, as NICE notes, the focus of clinical care remains on behavioural interventions, carer support, and licensed medicines when appropriate. Cannabis-based products remain experimental in this context and are not part of recommended dementia treatment pathways. 

Findings From Systematic Reviews and Meta-Analyses 

Limited And Inconsistent Results 

Systematic reviews published between 2023 and 2025 consistently report mixed or inconclusive findings. A 2024 PubMed meta-analysis of cannabinoids for neuropsychiatric symptoms found that while some small studies reported minor reductions in agitation, most results were modest, inconsistent, or statistically insignificant (PubMed Meta-Analysis). 

A 2023 double-blind crossover trial involving 21 older adults (mean age 85) found no significant improvements in behavioural symptoms, pain, or quality of life compared with placebo, though agitation scores improved slightly in the cannabinoid group (PubMed Study). 

Tolerability And Safety 

Across most studies, cannabinoids were generally well tolerated, with mild side effects such as drowsiness, dizziness, and confusion. However, safety concerns remain for frail, elderly populations where even small cognitive or balance changes can increase fall risk. Reviews highlight the need for larger, longer-term studies to confirm both efficacy and safety. 

Feasibility Studies and European Research 

A Swiss feasibility study published in 2024 tested a THC/CBD oil formulation for severe dementia. It found that treatment was feasible and tolerated, with caregivers reporting some improvements in calmness and sleep, but outcomes were not statistically significant (Swiss Study). The authors concluded that cannabinoids may be a potential adjunct to research protocols but are not yet suitable for clinical recommendation. 

What UK Guidelines Say 

According to NHS and NICE, medical cannabis can only be prescribed under specialist supervision for a few licensed conditions, such as severe epilepsy, chemotherapy-induced nausea, and spasticity in multiple sclerosis, not dementia (NHS Guidance). 

NICE surveillance updates confirm that both NG97 and NG144 do not recommend cannabinoids for dementia symptoms, citing lack of robust clinical evidence and ongoing safety uncertainties. 

The Alzheimer’s Society UK also echoes this position, stating that there is no reliable evidence that cannabis or CBD oil can prevent, slow, or treat dementia. It highlights that many studies are small, unregulated, or limited by inconsistent dosing and outcome measures (Alzheimer’s Society). 

Expert Opinions from Major Health Bodies 

The World Health Organization (WHO) maintains that there is no conclusive clinical evidence supporting cannabinoids for dementia-related symptoms and warns that data on long-term use in elderly or cognitively impaired populations remains inadequate. Similarly, most UK clinical experts agree that while research should continue, cannabis-based products should be used only within formal trials, not routine care (WHO: Cannabis and Cannabinoids). 

The 2023 NICE surveillance review explicitly confirmed that no new evidence since 2020 has changed this stance. Until large, randomised controlled trials demonstrate clear benefit, NICE does not plan to update its guidance to include cannabis-based treatments for dementia. 

The Clinical Bottom Line 

  • Systematic reviews and NICE surveillance reports show no consistent clinical benefit of cannabis for dementia symptoms. 
  • Small studies have found modest improvements in agitation, but no effects on cognition, mood, or overall function. 
  • Safety and dosing remain major uncertainties in frail, elderly populations. 
  • NICE, NHS, and WHO do not recommend cannabinoids for dementia outside research trials. 
  • Any potential role for cannabis in dementia care remains investigational, not therapeutic. 

Educational Context: AlleviMed 

Educational platforms such as AlleviMed provide reliable information about how medical cannabis eligibility is assessed in the UK. They explain that prescribing remains tightly regulated and restricted to licensed indications only. AlleviMed focuses on public education, helping patients and caregivers understand the difference between research use and approved medical pathways. 

Takeaway 

Although medical cannabis has gained attention as a possible aid for behavioural symptoms in dementia, research reviews consistently show that evidence remains inconclusive. NICE, NHS, and Alzheimer’s Society guidance do not support cannabis-based treatments for dementia symptoms in clinical practice. For now, the most effective approach involves person-centred dementia care, behavioural management, and specialist medical guidance. Cannabis-based treatments may hold future promise, but only as part of regulated research, not as routine therapy. 

Julia Sutton, MSc
Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy. 

Dr. Clarissa Morton, PharmD
Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy. 

Categories